Aim: To investigate the significance of electrocardiographic and echocardiographic findings in patients with chronic kidney disease, specifically focusing on their lipid profile. Material and Methods: This research comprised 100 individuals who were diagnosed with chronic kidney disease. The diagnosis was made based on a combination of their medical history, clinical symptoms, compromised renal function tests, and abdominal ultrasonography. A comprehensive clinical history and physical examination were conducted, and the results was documented. Every patient in the research had biochemical testing such as complete blood count (CBC), renal function tests, lipid profile, and ultrasonographic examination of the abdomen. These tests were conducted to establish the existence of end-stage renal illness and evaluate the echocardiographic findings of the heart. Results: LVH was detected in 41% of the individuals, whereas ST changes were seen in 24% of the subjects in the electrocardiogram (ECG) analysis conducted in our research. LVH (left ventricular hypertrophy) and DDF (diastolic dysfunction) were the most prevalent abnormalities detected in 46% and 43% of the patients, respectively, according to the ECHO diagnoses. The present research reveals that the most prevalent cardiac abnormality among the Echo findings is left ventricular hypertrophy (LVH), which is seen in 46% of patients. This is followed by left ventricular diastolic dysfunction, which is detected in 43% of patients, and left ventricular systolic dysfunction, which is present in 29% of patients. In our research, the average triglyceride level was significantly higher in chronic kidney disease (CKD) patients on hemodialysis compared to CKD patients not undergoing hemodialysis, specifically measuring at 166.11 ± 13.54. The average VLDL level was significantly greater in CKD patients on hemodialysis compared to CKD patients not undergoing hemodialysis, specifically at a mean value of 32.21 + 3.43. Conclusion: Hemodialysis efficiently decreases the buildup of nitrogenous waste products, but it does not fully treat uremic dyslipidemia. Instead, it may modify the pattern of dyslipidemia, as seen in our work. CKD patients on hemodialysis had elevated levels of triglyceride and VLDL, while experiencing reduced levels of HDL, compared to CKD patients not undergoing hemodialysis.